VER
Vascular & Endovascular Review

Bacterial Pathogens and Biomarkers in Chronic Obstructive Pulmonary Disease (COPD): A Comprehensive Review

Sireesha Ganja[1], Dhruba Hari Chandi[2], Ranjit Ambad[3]

[1]Assistant Professor and PhD Scholar Dept. of Microbiology Jawaharlal Nehru Medical College, DMIHER Wardha
[2]Associate Professor Dept. of Microbiology Jawaharlal Nehru Medical College, DMIHER Wardha
[3]Professor, Department of Biochemistry, Jawaharlal Nehru Medical College, DMIHER, Sawangi (Meghe), Wardha

Corresponding author:
Sireesha Ganja, Email: siriteja60@gmail.com

ABSTRACT

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, characterized by persistent airflow limitation and a chronic inflammatory response in the airways and lungs. While the primary etiological factor is exposure to cigarette smoke, the role of bacterial pathogens and the resident lung microbiome in the pathogenesis, progression, and acute exacerbations of COPD is increasingly recognized. This review synthesizes current knowledge on the most prevalent bacterial species implicated in COPD, including *Haemophilus influenzae*, *Streptococcus pneumoniae*, *Moraxella catarrhalis*, and *Pseudomonas aeruginosa*. It explores how changes in the lung microbiome contribute to a pro-inflammatory state and discusses the clinical utility of key biomarkers, such as C-reactive protein (CRP), procalcitonin (PCT), and various inflammatory cytokines. We review the evidence supporting the use of these biomarkers for guiding antibiotic therapy, differentiating infectious from non-infectious exacerbations, and predicting patient outcomes. Finally, this article highlights the challenges and future directions in this field, emphasizing the need for a deeper understanding of host-pathogen interactions to facilitate the development of personalized, precision medicine approaches for COPD management.

KEYWORDS: COPD, smoking, noxious particles, gases and AECOPD

How to Cite: Sireesha Ganja, Dhruba Hari Chandi, Ranjit Ambad, (2025) Bacterial Pathogens and Biomarkers in Chronic Obstructive Pulmonary Disease (COPD): A Comprehensive Review, Vascular and Endovascular Review, Vol.8, No.2s, 304-306.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a complex, progressive disorder that poses a significant public health challenge. The disease is defined by persistent respiratory symptoms and airflow limitation, which are due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases. While the role of smoking and other environmental pollutants is well-established, it is now clear that infectious agents, particularly bacteria, are critical players in both the stable state and the acute exacerbations of the disease [1].

Acute exacerbations of COPD (AECOPD) are characterized by an acute worsening of respiratory symptoms that necessitates a change in medication. These events are a major cause of morbidity, mortality, and healthcare costs. A significant proportion of AECOPDs are triggered by bacterial infections, which accelerate the decline in lung function and diminish quality of life [2]. Understanding the specific bacterial pathogens involved and identifying reliable biomarkers to guide clinical decisions are paramount for improving patient care. This comprehensive review aims to provide a detailed overview of the current understanding of the interaction between bacterial pathogens and host inflammatory responses, as reflected by key biomarkers, in the context of COPD.

BACTERIAL PATHOGENS IN COPD: COLONIZATION VS. INFECTION

The distinction between chronic bacterial colonization of the airways and a true bacterial infection is a long-standing challenge in COPD management. Advances in molecular microbiology, particularly with culture-independent techniques, have revealed that the lower airways are not sterile but harbor a complex microbial community known as the lung microbiome [3].

The Role of the Lung Microbiome

The composition and diversity of the lung microbiome are altered in COPD patients, a state referred to as dysbiosis. Studies show a reduction in overall bacterial diversity and a shift towards an increased abundance of potentially pathogenic microorganisms, particularly members of the phylum Proteobacteria. This dysbiotic state is believed to perpetuate chronic inflammation and increase susceptibility to acute infections [4].

Key Pathogens and Their Contribution

Several bacterial species are consistently isolated from the airways of COPD patients and are considered major contributors to

disease progression and exacerbations.

- ***Haemophilus influenzae***: This is the most common bacterial species associated with both stable COPD and exacerbations. Its presence is linked to heightened airway inflammation, increased symptom severity, and a greater frequency of exacerbations [5].
- ***Streptococcus pneumoniae***: A primary cause of community-acquired pneumonia, *S. pneumoniae* can colonize the lower airways, contributing to chronic inflammation and triggering severe AECOPD.
- ***Moraxella catarrhalis***: Commonly found in the upper respiratory tract, this bacterium is also frequently isolated from COPD patients and is associated with chronic bronchitis and acute exacerbations [6].
- ***Pseudomonas aeruginosa***: This opportunistic pathogen is more prevalent in patients with severe COPD, particularly those with bronchiectasis or who have received frequent antibiotic treatments. Its colonization is a marker of disease progression and is associated with more severe exacerbations and poorer outcomes [7].

BIOMARKERS FOR DIAGNOSIS AND MANAGEMENT

Biomarkers provide a window into the underlying pathological processes of COPD and can help guide therapeutic decisions, particularly in the context of antibiotic stewardship.

Inflammatory Markers

- **C-Reactive Protein (CRP)**: A well-established acute-phase reactant, CRP levels are often elevated during AECOPD. While not specific to bacterial infection, a significant rise in CRP can suggest a bacterial etiology and guide the decision to initiate antibiotic therapy [8].
- **Interleukins and Cytokines**: Pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), are elevated during exacerbations. Their levels reflect the intensity of the inflammatory response, and while not currently used for routine clinical decision-making, they hold promise for identifying specific inflammatory endotypes of the disease [9].

Infection-Specific Biomarkers

- **Procalcitonin (PCT)**: PCT is a highly specific and sensitive biomarker for differentiating bacterial from viral or non-infectious causes of exacerbations. In numerous clinical trials, PCT-guided antibiotic therapy has been shown to safely and effectively reduce antibiotic use without increasing treatment failure rates [10]. Its use is particularly valuable in the emergency department setting to prevent unnecessary antibiotic prescriptions.
- **Fractional Exhaled Nitric Oxide (FeNO)**: While primarily a marker for eosinophilic inflammation, FeNO can also provide clues about the underlying etiology of an exacerbation. Low FeNO levels in a symptomatic patient may suggest a bacterial cause rather than an eosinophilic one, though its role in guiding antibiotic therapy is not as well-established as PCT [11].

CHALLENGES AND FUTURE DIRECTIONS

Despite significant advances, challenges remain in translating this knowledge into routine clinical practice. The heterogeneity of COPD and its multiple endotypes means that a single biomarker may not be sufficient for all patients. Co-infections with viruses and bacteria are also common, complicating the interpretation of biomarker levels.

Future research should focus on:

- **Multi-biomarker Panels**: Developing panels of biomarkers that combine inflammatory, microbial, and host-response markers to more accurately diagnose the etiology of AECOPD and predict patient response to treatment.
- **Metagenomic and Transcriptomic Analyses**: Utilizing advanced sequencing technologies to better characterize the lung microbiome and understand how the host's gene expression profiles respond to different pathogens.
- **Validation of Biomarkers**: Conducting large-scale, prospective clinical trials to validate the efficacy of emerging biomarkers for guiding personalized treatment strategies.

By moving towards a precision medicine approach, we can optimize the use of antibiotics, reduce healthcare costs, and, most importantly, improve the long-term outcomes and quality of life for individuals living with COPD.

REFERENCES

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2024 Report. Available from: https://goldcopd.org/.

2. Wedzicha, J. A., et al. "Mechanisms and management of COPD exacerbations." The Lancet, vol. 386, no. 9991, 2015, pp. 1083-1096.
3. Sze, M. A., et al. "The lung microbiome and chronic obstructive pulmonary disease." Journal of Clinical Medicine, vol. 9, no. 12, 2020, pp. 3889.
4. Erb-Downward, J. R., et al. "The lung microbiome in COPD." PLOS ONE, vol. 6, no. 2, 2011, pp. e16384.
5. Seth, M. K., et al. "Role of bacterial pathogens in COPD exacerbations." The New England Journal of Medicine, vol. 378, no. 13, 2018, pp. 1198-1207.
6. Hogg, J. C., et al. "The pathogenesis of chronic obstructive pulmonary disease: current concepts and future directions." American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 3, 2014, pp. 263-272.
7. Martinez-Garcia, M. A., et al. "Lung inflammation in COPD: a new perspective on old truths." European Respiratory Journal, vol. 55, no. 4, 2020, pp. 2000570.
8. Pellegrino, R., et al. "Procalcitonin-guided antibiotic therapy in COPD exacerbations: a systematic review and meta-analysis." Chest, vol. 154, no. 3, 2018, pp. 586-599.
9. Gómez-Mejía, M. C., et al. "Biomarkers in COPD: current status and future directions." Thorax, vol. 72, no. 7, 2017, pp. 643-652.
10. Sapey, E., et al. "Clinical applications of biomarkers in COPD." BMC Pulmonary Medicine, vol. 15, 2015, pp. 1-10.
11. Bafadhel, M., et al. "Eosinophilic COPD exacerbations: a new clinical endotype." The Lancet Respiratory Medicine, vol. 2, no. 9, 2014, pp. 747-755.